Drugs / bismuth tripotassium dicitrate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT04713670 | Mar 2021 → Dec 2025 overdue | Helicobacter pylori infectious disease | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT02788123 | Mar → May 2017 | stomach disorder | Astellas Pharma Europe B.V. | Terminated | No outcome recorded Stop: Business |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07144657 Background | Sep 2025 → Dec 2029 expected | gastric mucosa-associated lymphoid tissue lymphoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bismuth tripotassium dicitrate | “bismuth tripotassium dicitrate 300 mg three times a day” NCT04713670 ↗ |
| Route | Oral | “Bismuth tripotassium dicitrate 300 mg 1# qid PO Days 1-14” NCT07144657 ↗ |